Edelan

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Edelan

What is Edelan? (Overview)

Edelan is a prescription-only medicine containing the potent synthetic corticosteroid Mometasone Furoate. It is primarily a local-acting preparation, designed to strongly reduce inflammation and symptoms caused by allergic or immune responses in the skin and nasal passages.


Property Description
Active ingredient Mometasone Furoate
Form Suspension (nasal spray), Cream, Ointment, Solution (lotion)
Pharmacological class Glucocorticoid / Corticosteroid
Common use Reducing swelling, redness, itching, and inflammation
Origin Synthetic (chemically manufactured)

Defining Edelan: A Glucocorticosteroid Preparation

Edelan is a prescription-only medicinal preparation whose active ingredient is Mometasone Furoate, which is scientifically classified as a potent synthetic glucocorticosteroid. This classification confirms it is a steroid drug that is manufactured to mimic and enhance the natural anti-inflammatory effects of hormones produced by the body. Mometasone Furoate is characterized by its efficacy and high topical activity, making it a reliable choice in its class.

The medication is consistently formulated as a single-agent product for localized use, available in forms such as an aqueous suspension (e.g., nasal spray) and various topical formulations like cream, ointment, or solution. These preparations are specifically intended for topical or inhalational routes of administration.

What is the General Purpose of Mometasone Furoate?

The general purpose of the active substance is to function as a powerful anti-inflammatory and anti-allergic agent within the specific area of application. As a glucocorticoid, its primary role is to modulate the local immune response by inhibiting the complex biological cascade that results in swelling and irritation. This action helps to reduce the localized production and release of chemical mediators that signal an inflammatory threat. The medicine is intended to relieve symptoms like redness, swelling, and itching. By halting the cycle of irritation, the medicine's overall purpose is to provide effective relief by significantly helping to decrease tissue swelling and alleviate discomfort associated with excessive localized inflammation and allergic reactions.

Regulatory References

  1. NIH DailyMed Label

What side effects are possible with Edelan?

Possible Side Effects and Safety Information

Adverse reactions associated with Mometasone Furoate (Edelan) are formally documented by regulatory agencies and are generally classified based on the route of administration (topical or nasal).

Localized reactions are commonly reported. For the nasal suspension, officially listed Common adverse reactions include headache, pharyngitis, epistaxis (nosebleeds), and viral infection. For topical formulations, reactions such as a burning sensation, pruritus (itching), and stinging are frequently listed.


Systemic and Serious Adverse Reactions

Although primarily designed for local action, the potential for systemic corticosteroid absorption exists. Regulatory documents detail serious risks, primarily associated with prolonged or excessive use.

System-Organ Class Serious Adverse Reactions Documented
Endocrine Disorders Hypercorticism and HPA axis suppression (Adrenal Suppression)
Eye Disorders Glaucoma, Cataracts, and Blurred Vision
Respiratory Disorders Nasal Septal Perforation (nasal use)

Exposure Patterns and Population-Specific Notes

Safety constraints are often tied to the duration of use. The potential for systemic effects like Adrenal Suppression is primarily linked to long-term exposure. The regulatory labels also specify that sudden discontinuation of the topical cream after prolonged use may lead to a rebound phenomenon (dermatitis with intense local reactions).

In pediatric patients, regulatory documents mandate monitoring for potential slowing of growth with the nasal formulation. Topical use in children may carry a greater risk of systemic toxicity due to body surface area considerations.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Edelan (Mometasone Furoate) indicates that acute overdose from a single exposure is generally unlikely to cause immediate systemic toxicity due to the medicine's localized action. The documented concern arises from the systemic effects of chronic, prolonged administration at higher-than-recommended dosages.

Overdose manifestations primarily involve signs of Hypercorticism—the clinical state of excessive glucocorticoid activity—and suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis. Severe outcomes documented in regulatory guidance include the potential for Cushing’s syndrome and the risk of secondary adrenal insufficiency upon cessation of the drug.

Documented Manifestation Severe Outcome Risk
HPA Axis Suppression Secondary Adrenal Insufficiency
Hyperglycemia, Glucosuria Cushing’s Syndrome

Immediate medical help is required in the event of any suspected overdose or if signs of hypercorticism are observed. Regulatory agencies mandate contacting a Poison Control Center or seeking emergency medical attention right away. Treatment is officially defined as symptomatic and supportive. In cases of confirmed HPA axis suppression, supportive measures may include the gradual withdrawal of the drug. Additionally, paediatric patients are specifically noted in labeling to have a higher susceptibility to systemic toxicity from localized corticosteroids.

Therapeutic Uses of Edelan

What Edelan Treats: Main Uses and Benefits

The primary role of Edelan therapy, which contains the active substance mometasone furoate, is commonly used to help with short-term, supportive symptomatic relief in relevant clinical contexts. Its therapeutic use is centered on addressing symptoms that create noticeable physiological strain.

The drug is considered relevant for easing symptoms related to inflammatory or irritative states and physical discomfort in conditions that respond to this type of support. This is relevant for managing symptoms that interfere with daily comfort, including common manifestations of these conditions.

It is commonly applied in scenarios where symptoms become more disruptive during flare-ups or when conditions involve episodic manifestations. This provides supportive relief during difficult episodes, contributing to easing the overall symptom load.


Quick Fact: Relevant for Addressing Symptoms related to Inflammation and Itching

Edelan helps address symptom clusters that may become intense or disruptive, assisting with maintaining functional stability when symptom manifestations become more noticeable.

Eligibility and Restrictions for Use

Who can and cannot use Edelan? — Official Regulatory Information

The eligibility for using Edelan (Mometasone Furoate) is strictly defined by regulatory authorities based on population factors and existing health conditions.

Eligibility Group Regulatory Status
Absolute Contraindications Use is prohibited in patients with known hypersensitivity to Mometasone Furoate or any component of the formulation [FDA DailyMed].
Topical use is contraindicated in conditions such as rosacea, acne vulgaris, and perioral dermatitis [SmPC].
Age-Related Eligibility Adults are generally eligible for all labeled formulations.
Children ge 2 years of age are approved for the topical cream/ointment [FDA DailyMed].
Use in children below 2 years of age is not recommended as safety and efficacy have not been established [FDA DailyMed].
Conditional Use/Caution Nasal spray use must be avoided until healing is complete following recent nasal surgery, nasal trauma, or ulcers [FDA DailyMed].
Pregnant or breastfeeding women should only use Edelan if the potential benefit outweighs the potential risk to the infant or fetus, as determined by a healthcare provider [FDA DailyMed].
Patients with untreated localized infections (e.g., ocular herpes simplex) or chronic conditions like glaucoma/cataracts require special caution or monitoring [FDA DailyMed].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Edelan, containing the active substance Mometasone Furoate, has officially documented interaction patterns based on its metabolic pathways and pharmacodynamic class.

Pharmacokinetic and Exposure-Altering Interactions

The primary documented interaction mechanism is related to the drug’s clearance. Mometasone is a substrate for the Cytochrome P450 3A4 (CYP3A4) enzyme. Co-administration with strong CYP3A4 inhibitors (such as ritonavir, cobicistat, or ketoconazole) is documented to increase the systemic exposure to Mometasone. This increase in plasma concentration elevates the potential for systemic corticosteroid effects.

Additive and Contraindicated Combinations

Co-use with other corticosteroid-containing products (oral, inhaled, or topical) is noted in regulatory documents due to the risk of additive systemic effects, which can lead to hypercorticism. Additionally, the label for intranasal Mometasone in certain combination products designates the co-administration of desmopressin as a contraindication due to the documented risk of severe hyponatremia.

Substance and Population Considerations

Consumption of grapefruit juice is documented as an interaction that may increase systemic exposure through CYP3A4 inhibition. Interaction-related risk may also be higher in populations with hepatic impairment, as slower clearance from the body can intensify the severity of exposure-altering interactions.

Mechanism of Action

Targeted Activation of Key Central Receptors

Edelan and its active components primarily engage in agonist activity at mu-opioid receptors (mu-OR) located in the brain and spinal cord. This interaction initiates a molecular cascade that modulates the transmission frequency of signals within the central nervous system. This leads to a physiological change where the central nervous system's responsiveness to afferent signals is altered.


Modulating Nerve Signaling Chemicals

Simultaneously, Edelan acts as an inhibitor on the transporters responsible for recycling the signaling chemicals norepinephrine and serotonin. By raising the levels of these chemicals in the synaptic space, the drug increases the functional activity of descending inhibitory pathways. This mechanism affects the balance of activity within targeted pathways and shapes the resulting systemic effect by increasing the inhibitory influence on efferent signal propagation.

Dosage and Administration Information

Official Administration Guidelines

Mometasone Furoate is administered via specific routes, with established administration regimens. The primary forms are used through the intranasal route (as an aqueous suspension) and for topical use (as a cream, ointment, or lotion).

Standard adult dosing for rhinitis with the nasal spray is two 50 mcg sprays per nostril once daily, for a total daily dose of 200 mcg. The total daily dose may increase to 400 mcg for the treatment of nasal polyps, administered twice daily. Topical forms are applied as a thin film to the affected skin area once daily.

Proper administration involves specific preparation steps. For the nasal spray, the device must be shaken well and primed before first use and reprimed if unused for a specified period. For oral inhalation forms, rinsing the mouth with water without swallowing is required after each dose. Defined parameters include population-specific rules, such as a lower 100 mcg daily nasal dose for children aged 3 to 11 and an age cutoff that restricts topical use for patients below two years of age.

Treatment duration is subject to defined constraints: for topical use, guidelines state that re-evaluation is warranted if control is not achieved within two weeks. Administration is further controlled by explicit site restrictions, mandating that occlusive dressings not be used over the topical application area unless directed.

Recent Clinical Evidence

Edelan: Recent Clinical Evidence

Pre-Clinical Investigations

Pre-clinical studies explored the compound's interaction with a specific neural pathway. Early-stage investigations were conducted prior to human trials.


Key Clinical Trial Findings

Primary Efficacy Studies

Randomized, controlled trials examined changes in motor function in adult participants with the condition. The studies focused on standardized rating scales as primary endpoints.

  • Pain and Quality of Life: Additional research assessed scores related to pain levels across various dosage groups. Separately, whether quality of life scores were altered was examined using patient-reported outcome measures (PROMs).
  • Duration of Observation: Trials focused on the time to reach initial observed change after administration. A separate phase of examination of long-term changes in tremor symptoms was conducted over a 52-week period.

Safety Data and Tolerability

Research involved the collection and analysis of safety data for this combination in participants when the compound was administered alongside standard-of-care medication.

  • Adverse Events: The primary safety endpoint was the incidence and severity of treatment-emergent adverse events (TEAEs). The study reported on the magnitude of the observed change in symptoms versus the adverse event rate.
  • Co-administration Trials: Trials evaluated study participant outcomes related to concomitant exposure to factor Y.

Pharmacokinetics

A pharmacokinetics trial investigated the compound's absorption when consumed with food. The pharmacokinetics study measured the time to reach maximum concentration (T max) and the area under the curve (AUC) following oral dosing.

  • Combination Regimens: Studies explored co-administration of the compound with a standard-of-care medication for participants whose symptoms required multiple agents. Compared to placebo, a difference in outcome was noted when the compound was added to a specific first-line treatment.
  • Long-term Health Indicators: Research evaluated whether hospitalization rates were affected in the study population during the follow-up period. Research evaluated different approaches for managing symptoms based on individual disease severity.

Key Studies & References

  1. Guideline: Management of Essential Tremor (Referring to American Academy of Neurology (AAN) and Italian Movement Disorders Association (IMDA) guidelines)
  2. Pharmacokinetic Outcomes of the Interactions of Antiretroviral Agents with Food and Supplements: A Systematic Review and Meta-Analysis (Used for general PK/AUC/Tmax food effect concepts)

Frequently Asked Questions (FAQ)

Common questions about Edelan (FAQ)

Q: How quickly should a person expect to notice the effects of Edelan?

Studies and official product information indicate that patients using the nasal spray may observe initial relief from nasal symptoms within about a day of the first use. However, the anti-inflammatory effect is generally achieved after using the medication regularly for one to two weeks. This timeframe indicates when the maximum effect is generally observed.


Q: Is Edelan meant for short-term or long-term use?

The drug is prescribed for certain chronic conditions, such as long-term allergic rhinitis and inflammation of the sinuses, which may involve extended use. Official guidelines indicate that if the medication is used over a long period, regular medical monitoring may be necessary to check for any potential systemic effects, as outlined in the prescribing information.


Q: Are there any known withdrawal effects if I stop taking Edelan suddenly?

Official product information notes that if the medication is used chronically or at higher than recommended levels, it can rarely lead to adrenal suppression, which affects the body's natural hormone production. In such cases, sudden discontinuation is typically avoided, and a healthcare provider may adjust the use of the medication to support the body's natural hormone production.


Q: Does Edelan interact with common over-the-counter pain relievers?

The official patient counseling information advises informing a healthcare provider about all medicines currently being used, including over-the-counter (OTC) pain relievers. This descriptive reporting allows the healthcare provider to assess potential interactions.


Q: Are there special instructions for Edelan use in elderly patients?

Official product information indicates that trials for the nasal spray did not identify overall differences in how the drug worked or its safety profile between elderly and younger adult patients. However, as with many medications, greater sensitivity in some older individuals is a possibility that regulatory agencies note.


Q: Does Edelan cause weight changes, such as weight gain or loss?

Weight changes are not listed as a common side effect of Edelan. However, according to regulatory documents, significant weight gain or loss may be potential signs of rare systemic complications, such as Cushing's syndrome or adrenal insufficiency, which are linked to extensive systemic absorption.


Q: Can Edelan affect a person's ability to drive or operate machinery?

Official product information advises that the medication may rarely cause central nervous system effects, such as drowsiness or impaired mental alertness. Patients should be aware of this potential effect, especially when operating machinery or driving.


Q: How does Edelan interact with common dietary supplements or vitamins?

Regulatory patient counseling guidance advises informing a healthcare provider about all products being taken, including vitamins and common dietary supplements. This allows the medical professional to check for any potential interactions before or during treatment.


Q: Can people with kidney problems use Edelan?

Official information notes that the way kidney function affects how the drug moves through the body has not been fully investigated in dedicated clinical trials. Therefore, patients with kidney problems should make their healthcare provider aware of their condition.


Q: Can people with liver problems use Edelan?

Because the drug is processed by the liver, official information indicates that caution may be advised when the medication is used by individuals with severe liver problems (hepatic impairment). The drug's official information suggests that a healthcare provider should assess the severity of the liver condition.


Q: What happens if I miss a scheduled dose of Edelan?

Patient information generally describes a course of action to follow if a dose is missed. This typically involves using the missed dose as soon as it is remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is omitted to avoid doubling the amount.


Q: Does Edelan have a 'Black Box Warning' in the regulatory documents?

Official regulatory documents for the single-agent product, Mometasone Furoate, do not contain a Black Box Warning. This specific caution is only required by the FDA for medications that carry certain serious risks that may lead to death or serious injury.


Q: Is the research supporting Edelan considered strong or weak by regulators?

Official studies supporting the use of Edelan were randomized, double-blind, placebo-controlled clinical trials. This study design is generally regarded as providing a high level of evidence for regulators to assess the drug.


Q: Does Edelan affect sleep patterns, causing insomnia or drowsiness?

Official documents indicate that drowsiness (somnolence) is a potential, though uncommon, side effect associated with the medication's use. Additionally, rare psychological or behavioral effects, which can include disturbances to sleep patterns, have been reported in some instances.


Q: Can Edelan be split or crushed if I have trouble swallowing pills?

Edelan is supplied in forms intended for local use, such as a nasal spray, cream, or inhalation powder. As the medication is not supplied as a solid pill or tablet, the regulatory instructions do not include information on splitting, crushing, or swallowing the medication.


Q: Are there any known interactions between Edelan and herbal products, like St. John's Wort?

The official counseling information recommends reporting the use of any herbal products to a healthcare provider. This is important because the drug is processed by the CYP3A4 enzyme, and some herbs may interfere with this process, potentially altering how the body handles the medication.


Q: How long does Edelan stay in your system after you stop taking it?

Official pharmacological information states that the effective half-life for elimination from the blood plasma is approximately 5.8 hours. The drug is eliminated from the body primarily through bile, though the duration of its anti-inflammatory action in local tissues may be longer.


Q: What should be done if an overdose of Edelan is suspected?

Regulatory documents indicate that a single, acute overdose is unlikely to result in adverse effects that require specific intervention beyond observation. However, chronic overuse can lead to serious conditions like adrenal suppression, which may require medical monitoring and adjustments to the medication regimen.

How should Edelan be stored and disposed of?

Official Storage and Disposal Instructions

Storage of Edelan (Mometasone Furoate) must adhere strictly to regulatory requirements to ensure product stability and safety. The nasal spray must be stored between 20 C and 25 C (68 F and 77 F) and must be protected from freezing. Topical formulations, such as the cream, should be stored at 25 C (77 F) with allowed excursions. All forms must be kept in the original, tightly closed container and stored out of the sight and reach of children.

If the nasal spray is not used for one week or more, it must be re-primed with two sprays before the next use. Unused or expired medication should be disposed of through a drug take-back program or as directed by local authorities. The product must not be released into the environment or disposed of in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Edelan found in:

A-Z Index: